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cell populations without changes in cell division (as measured by
Ki67 expression) and recent thymic emigrants (as measured by T
cell receptor excision circles TREC) were observed with 4-week
courses of IGF-1 treatment. Signiﬁcantly, these changes were not
observed in similarly treated thymectomized mice, indicating that
effects of IGF-1 on peripheral T cell populations resulted primar-
ily from enhanced thymic output. IGF-1 administration also af-
fected thymic epithelial cell (TEC) turnover as measured by BrdU
incorporation, with observable shifts in TEC subpopulations in the
thymic cortex and medulla as enumerated by ﬂow cytometry.
Immunohistoﬂuorescence of extracellular matrix (ECM) in IGF-1
treated young, aged, and RAG KO mice were signiﬁcant for
changes in laminin distribution. Finally, mice lacking IGF-1 re-
ceptor (IGF-1R) signaling on T cells were generated through T
cell speciﬁc cre-mediated deletion of the IGF-1R high-afﬁnity
binding site (LCK-cre/loxIGF1R). Compared to wild-type litter-
mates, LCK-cre-loxIGF1R mice exhibited a decrease in the num-
ber of CD4 CD8 thymocytes, thymic TREC, splenic naive T
cell populations, and splenic TREC. These results demonstrate: (1)
IGF-1 enhances the recruitment of thymocyte precursors, expands
thymocyte subpopulations, and increases thymic output; (2) IGF-1
affects TEC turnover and ECM distribution, suggesting a mech-
anism by which IGF-1 inﬂuences thymocyte development; and (3)
IGF-1R signaling is required for the maintenance of normal thy-
mocyte and peripheral T cell populations. Together, the results
support the concept of the use of neuroendocrine growth factors
such as IGF-1 in preserving and/or enhancing recovery of thymic
function following HSCT.
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ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN SPECIFIC CD8 MEMORY
CELLS RESPOND DIFFERENTLY TO ANTIGEN AND ANTIGEN-INDEPEN-
DENT ACTIVATION IN THE SPLEEN AND MARROW COMPARTMENTS
FOLLOWING HCT
Shatry, A.1, Levy, R.B.1 University of Miami Miller School of Medicine,
Miami, FL.
We are interested in studying how CD8 memory cells respond in
recipients following progenitor cell transplants. Antigen-speciﬁc
CD8 TM against the immunodominant H60 antigen in B6 mice
contribute to resistance against MHC-matched BALB.B marrow.
To examine CD8 TM responses to this antigen, B6 mice were
sensitized 2 with BALB.B antigen (B6BALB.B) and 1, 5, and 22
days later, H60-speciﬁc CD8 TM in the spleen and marrow were
analyzed for degranulation as assessed by CD107a expression. One
day following antigen administration, degranulation by CD8 TM
was equivalent (90%) in host spleen and marrow. Five days later,
degranulation of splenic H60 CD8 TM (60%) was 3 higher
(22%) versus cells in the marrow compartment. These levels de-
creased to 25% and 12%, respectively, in the spleen and marrow 3
weeks post antigen boost. These results indicated that CD8 TM
effector-like activity is induced asymmetrically in the 2 compart-
ments and this activity may be differentially regulated in these
locations. We then compared MiHA-speciﬁc CD8 TM in the
marrow and spleen after antigen-independent (lymphopenia) acti-
vation. Highly enriched (	95% pure) CFSE labeled or unlabeled
donor splenic CD8 T cells from B6BALB.B mice were adoptively
co-transplanted with syngeneic marrow to ablatively conditioned
(9.0 Gy) syngeneic hosts. Three days post-transfer, donor CD8
TM in recipient marrow and spleen were analyzed for CFSE
dilution and degranulation including H60 CD8 TM cells. Donor
H60 CD8 TM in the marrow underwent multiple cycles of
division in contrast to the spleen, indicating that the marrow
compartment provided superior support for this initial homeostatic
proliferation. Interestingly, 92% of donor H60 CD8 TM in
recipient spleens expressed CD 107a compared to 42% in the
marrow compartment. In total, these ﬁndings indicate that whereas
the marrow supported greater homeostatic proliferation of donor
CD8 TM versus the spleen, the latter compartment was the pre-
ferred site for effector-like activity induced by lymphopenic con-
ditions. These ﬁndings underscore the importance of hematopoi-
etic compartments in shaping the diversity and differentiation of
allospeciﬁc CD8 TM responses in the transplant setting.
227
IMMUNE MONITORING WITH iTAGTM MHC TETRAMERS FOR PREDIC-
TION OF RECURRENT OR PERSISTENT CYTOMEGALOVIRUS (CMV) IN-
FECTION IN ALLOGENEIC STEM CELL TRANSPLANT (SCT) RECIPIENTS:
A PROSPECTIVE MULTICENTER CLINICAL TRIAL
Boeckh, M.1, Nakamura, R.2, Cornelissen, J.J.3, Zaia, J.A.2, Forman,
S.J.2, Gaal, K.2, Brooimans, R.A.3, Gratama, J.W.3, Gasior, G.H.4,
Sullivan, L.A.4, Boyce, C.S.4, Southwick, P.C.4 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. City of Hope National Medical
Center, Duarte, CA; 3. Erasmus Medical Center, Rotterdam, Nether-
lands; 4. Beckman Coulter, San Diego, CA.
Background: CMV infection is an important cause of morbidity
and mortality in SCT recipients despite the introduction of routine
post-transplant virologic monitoring and the use of potent antiviral
agents. This prospective multicenter study evaluated the use of
tetramers in monitoring CMV-speciﬁc T cell recovery following
allogeneic SCT to predict patients at risk for CMV-related com-
plications. Methods: Patients were tested every 2 weeks and mon-
itored for up to 1 year post-transplant. iTAg™ MHC Tetramers
(Beckman Coulter, San Diego) were used to enumerate CMV-
speciﬁc CD8 T cells by ﬂow cytometry using a single-platform
absolute counting method. The following tetramers were included:
pp50: A0101 VTEHDTLLY; pp65: A0201 NLVPMVATV,
B0702 TPRVTGGGAM, B3501 IPSINVHHY; IE-1: B0801
ELRRKMMYM. All patients underwent weekly surveillance by
pp65 antigenemia or DNAemia with preemptive antiviral therapy.
Results: Data were analyzed for 83 CMV-seropositive recipients
with 3 or more tetramer values. Median follow-up was 9 months
(range 2–12). Delayed recovery of CMV-speciﬁc CD8 T cells
(7 cells/mL in all blood samples during the ﬁrst 65 days post-
transplant) predisposes patients to CMV-related complications
(Table 1). These patients are 2.6 times more likely to develop
recurrent or persistent CMV infection, 4.8 times more likely to
develop CMV disease, 2.4 times more likely to develop fatal com-
plications, and 2.2 times more likely to develop one of more of
these outcomes than patients showing rapid recovery. Rapid re-
covery (7 cells/mL in any blood sample during the ﬁrst 65 days
post-transplant) was associated with protection from CMV-related
complications. Inter- and intraassay variability of the assay was
8% and 8%, and results were available in 3 hours. Conclu-
sions: CMV tetramer-based immune monitoring, in conjunction
with virologic monitoring, can be an important new tool that
permits clinicians to assess the period of risk of CMV-related
complications and to make appropriate preemptive therapeutic
choices in managing allogeneic SCT patients. For high-risk pa-
tients with delayed immunologic recovery, virologic monitoring,
CMV tetramer monitoring, and other preemptive strategies should
be continued beyond 100 days post-transplant. For low-risk pa-
tients (7 tetramer-positive cells/mL), studies are needed to de-
termine how long virologic monitoring should be continued or if
preemptive therapy may be modiﬁed or instituted at higher viral
load levels (Table 1).
Table 1. Relative Risk
Recurrent or
Persistent
CMV Infection
CMV
Disease
Transplant-
Related
Mortality
Composite
(one or More
of These
Outcomes)
Delayed recovery
of CMV-specific
CD8 cells
(< 7 cells/uL)
2.6 4.8 2.4 2.2
P  .02 P  .09 P  .12 P  .01
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EFFECTS OF THYMOGLOBULIN ON LYMPHOCYTE L-SELECTIN-MEDI-
ATED ADHESIVE INTERACTIONS
Buzney, C.1, Lee, J.1, Sackstein, R.1,2 1. Brigham and Women’s Hos-
pital/Harvard Medical School, Boston, MA; 2. Dana-Farber Cancer
Institute, Boston, MA.
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Antithymocyte globulins (ATG) such as rabbit ATG (Thymo-
globulin) are immunosuppressive agents known to deplete T cells,
and there is increasing evidence that they may also affect T cell
migration. In this study, we sought to determine if Thymoglobulin
affects L-selectin-dependent lymphocyte binding to lymph node
high endothelial venules (HEV), the ﬁrst step in migration of
lymphocytes to lymph nodes. Human peripheral blood lympho-
cytes were collected by Ficoll centrifugation of citrated blood and
T cells were isolated by magnetic bead separation. T cells were
exposed to Thymoglobulin at 10, 20, 30, 40, and 50 ug/ml for 30
minutes at 4° C; controls consisted of puriﬁed rabbit immunoglob-
ulin at identical concentrations. The capacity of T cells to engage
HEV was measured by Stamper-Woodruff assay. Additionally,
parallel plate ﬂow chamber studies were performed under physio-
logic shear stress conditions to measure T cell binding to L-
selectin ligands expressed on the hematopoietic cell line, KG1a.
Incubation of T cells with Thymoglobulin led to a dose-dependent
decrease in binding to HEV, with complete abrogation at 50
ug/ml. Similarly, Thymoglobulin blunted L-selectin-mediated
binding interactions in parallel plate ﬂow studies. Flow cytometry,
performed using a variety of anti-L-selectin mAb showed, ironi-
cally, that incubation of T cells with Thymoglobulin resulted in an
increase in the percent marker cells and the mean channel ﬂuo-
rescence for L-selectin epitopes targeted by mAbs TQ-1 and
LAM1-116, with no change in the levels of the DREG56 epitope.
These changes were speciﬁc for L-selectin, as there were no
changes in expression of VLA-4 using the same conditions. Im-
portantly, as shown by analysis of Thymoglobulin immunoprecipi-
tates of biotinylated T cells, Thymoglobulin does not directly
recognize L-selectin. These ﬁndings indicate that the effects of
Thymoglobulin on L-selectin function are not related to decreased
surface expression, but appear to be related to changes in L-
selectin topography affecting L-selectin’s capacity to engage its
ligand(s). Further studies are in progress to deﬁne the nature of
these changes and how modulation of L-selectin topography is
achieved by Thymoglobulin. Operationally, changes in L-selectin
function could have profound implications in the ability of circu-
lating lymphocytes to enter lymphoid tissues, inhibiting appropri-
ate antigen-recognition and subsequent generation of immune
responses.
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APOPTOTIC DONOR LEUKOCYTES INHIBIT TOLERANCE AND LIMIT
MIXED CHIMERISM INDUCED BY CD40-CD154 BLOCKADE IN ALLOGE-
NEIC BONE MARROW TRANSPLANTATION
Li, J.-M.1, Giver, C.R.1, Gorechlad, J.1, Larsen, C.P.2, Waller, E.K.1
1. Winship Cancer Institute, Emory University, Atlanta, GA; 2. The
Carlos and Marguerite Mason Transplantation Research Center, De-
partment of Surgery, Emory University, Atlanta, GA.
Background: “Mini” transplants using non-myeloablative con-
ditioning can avoid early post-transplant toxicity associated with
myeloablative conditioning prior to allogeneic hematopoietic pro-
genitor cell transplantation (HPCT), but graft-versus-host-disease
(GvHD) and graft rejection remain clinical problems. We previ-
ously found that low-dose busulfan conditioning and costimulatory
blockade using anti-CD154 monoclonal antibody (mAb) were suf-
ﬁcient to establish stable mixed chimerism without GvHD when
transplanting moderate doses of T cell depleted bone marrow
(TCD-BM) from MHC fully mismatched donors (Adams et al,
J Immunol 167:1103, 2001). Additionally, several groups have
shown that apoptotic cells can contribute to immune tolerance in
HPCT. Therefore, in an effort to enhance donor chimerism and
graft-versus-leukemia activity, we evaluated the ability of different
preparations of donor lymphocytes to provide a tolerizing effect
and facilitate stable donor chimerism when administered prior to
the BM graft. Methods: In B63B10BR and BALB/c3B6 MHC
fully mismatched transplant pairs, donor lymphocytes were treated
ex-vivo with different immunosuppressive regimens (ﬂudarabine,
psoralen-UVA, -irradiation) and used as tolerizing DLI 6 days
prior to HPCT, co-administered with anti-CD154 mAb and low-
dose busulfan conditioning. We also compared the use of donor
lymphocytes that had been enriched for, or depleted of, T cells or
CD11b/CD11b subsets as tolerizing DLI in the same “mini”-
transplant setting. Results: Long-term mixed-chimerism without
GvHD was enhanced by pre-transplant administration of viable
allogeneic splenocytes (Table 1). Unexpectedly, the use of apopto-
tic/necrotic donor splenocytes resulted in diminished donor en-
graftment. Puriﬁed splenic T cells more potently enhanced donor
chimerism compared to unfractionated splenocytes, T cell de-
pleted splenocytes, or the CD11b and CD11b fractions of
donor splenocytes. In a leukemia model, the survival of recipients
with mixed-chimerism following low-dose busulfan and co-stimu-
latory blockade was enhanced by viable post-transplant donor T
cell infusions. Conclusions: Host tolerance of donor cells follow-
ing non-myeloablative conditioning and co-stimulatory blockade is
an active process enhanced by viable donor immune cells. The
diminished donor chimerism obtained with apoptotic/necrotic do-
nor splenocytes suggests that dying cells interfere with the donor-
speciﬁc tolerance generated by anti-CD154 mAb.
Conditioning and Transplantation (B63B10BR)
Donor Chimerism (%)
(no. engraftment
[donor cells >1%] mice/
all mice in the group)
Tolerizing DLI
(3107) i.v. at d-6
	CD154
mAb (i.v. at
d-7, 6,
4, 2, 0,
& 6)
Busulfan
(i.p at d-1)
TCD-BM
(i.v at d0) d  30 d  60 d  160
No Tolerizing DLI no 20 mg/kg 2107 0 0 0
No Tolerizing DLI 500g 20 mg/kg 2107 42 10 35 21 44 20
Un-manipulated SP 500g 20 mg/kg 2107 65 7* 52 17* 79 7*
CD3() SP 500g 20 mg/kg 2107 ND 68 6* ND
CD11b() SP 500g 20 mg/kg 2107 ND 43 4 ND
Fludarabine
treated-SP
500g 20 mg/kg 2107 45 6 ND 52 4
PUVA treated-SP 500g 20 mg/kg 2107 33 13 ND 47 23
Irradiated-SP (7.5 Gy) 500g 20 mg/kg 2107 28 24* ND 42 22
Irradiated-SP (15 Gy) 500g 20 mg/kg 2107 12 15* ND 20 17*
Irradiated-SP (30 Gy) 500g 20 mg/kg 2107 2 4*
(5/10) no.
ND 4 7*
(4/10) no.
*P .05 vs recipients of No Tolerizing DLI with 
CD154 mAb at
same time point.
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RAPID IMMUNE RECONSTITUTION AND COMPLETE DONOR CHIMER-
ISM AFTER NON-MYELOABLATIVE ALLOGENEIC PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION (NMSCT) IN PEDIATRIC PATIENTS
(PTS) WITH MALIGNANCY
Fry, T.J.1, Rager, A.1,2, Hakim, F.3, Love, C.1, Layton, P.1,
Fowler, D.3, Bishop, M.R.3, Gress, R.3, Mackall, C.L.1, Wayne, A.S.1 1.
Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD; 2. Duke
University School of Medicine, Durham, NC; 3. Experimental Trans-
plantation and Immunology Branch, CCR, NCI, NIH, Bethesda, MD.
Background: Experience with NMSCT for pediatric cancer is
limited. Compared to adults, children and adolescents have less
immune depletion and improved reconstitution after chemother-
apy, which might increase the risk of graft rejection or mixed
chimerism. On the other hand, preserved host thymic function
might enhance donor-derived immune recovery. We postulated
that pre-transplant immune depletion followed by T cell replete
NMSCT would facilitate donor engraftment and enhance post-
transplant immune reconstitution. Methods: We piloted a novel
regimen in 21 pediatric pts (median age 14, range 4–21) with
high-risk hematologic malignancies and sarcomas. Fludarabine-
based induction chemotherapy was administered for disease con-
trol and targeted CD4 count reduction. Pre-transplant condition-
ing consisted of cyclophosphamide (1200 mg/m2/day) and
ﬂudarabine (30 mg/m2/day)  4 days plus melphalan (100 mg/m2
 1 dose in sarcoma pts). Grafts consisted of G-CSF mobilized
unmodiﬁed peripheral blood stem cells from 5-6/6 HLA-matched
ﬁrst-degree relatives (median CD34 dose 11.7  106/kg, range
4.4–19.1; median CD3 dose 416  106/kg, range 228–815). Cy-
closporine was used for GVHD prophylaxis. Results: Induction
therapy dramatically reduced CD4 counts. Donor-derived engraft-
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